Dipharma

Executive Summary

Dipharma is a well-established Contract Development and Manufacturing Organization (CDMO) and leading manufacturer of Active Pharmaceutical Ingredients (APIs), headquartered in Milan, Italy, with a history dating back to 1946. Operating four cGMP-compliant plants and commercial offices in Italy, the USA, and China, the company serves both the generic drug and pharmaceutical innovation sectors. Dipharma's long-standing expertise in API manufacturing and its global footprint position it as a reliable partner for pharmaceutical companies seeking high-quality, cost-effective drug substances. The company's private status allows for strategic flexibility, while its continued investment in manufacturing capabilities supports growth in the expanding CDMO market, driven by increasing demand for generic drugs and outsourced production. With a focus on regulatory compliance and operational excellence, Dipharma is poised to capitalize on the trend of pharmaceutical companies outsourcing non-core activities, particularly in the generic API space. The company's diversified geographic presence mitigates supply chain risks and enables access to key markets, including Europe, North America, and Asia.

Upcoming Catalysts (preview)

• Q4 2026Completion of capacity expansion at Italian manufacturing plant70% success
• Q2 2026Signing of long-term supply agreement with a major generics company60% success
• 2027FDA approval for new API manufacturing facility in the USA50% success